Plant ID: NPO16044
Plant Latin Name: Cupressus lawsoniana
Taxonomy Genus: Cupressus
Taxonomy Family: Cupressaceae
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
CNR1; CNR2; | |
TSHR; | |
FAAH; BLM; GLA; ALDH1A1; | |
TRPV1; | |
NFKB1; | |
SLCO1B3; SLCO1B1; |
Cytochrome P450 Enzymes: | CYP2C19; |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | CNR1 | Cannabinoid CB1 receptor | P21554 | CHEMBL218 |
Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0051001; negative regulation of nitric-oxide synthase activity | 6.403E-09 | 4.647E-05 | CNR1, CNR2, GLA |
MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 1.061E-06 | 3.851E-03 | CNR1, CNR2 |
BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 2.121E-06 | 6.510E-03 | CNR1, CNR2 |
BP | GO:0002376; immune system process | GO:0033004; negative regulation of mast cell activation | 1.940E-05 | 3.840E-02 | CNR1, CNR2 |
BP | GO:0050896; response to stimulus | GO:0043279; response to alkaloid | 2.158E-05 | 3.898E-02 | BLM, CNR1, TRPV1 |
BP | GO:0065007; biological regulation | GO:0045759; negative regulation of action potential | 2.327E-05 | 3.898E-02 | CNR1, CNR2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.633E-05 | 1.208E-03 | CNR2, CNR1, TRPV1, TSHR |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 8.014E-04 | 2.965E-02 | SLCO1B1, SLCO1B3 |
09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 1.612E-03 | 3.977E-02 | FAAH, CNR1 |
09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 2.901E-02 | 9.844E-02 | NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.812E-02 | 9.844E-02 | CYP2C19 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 5.441E-02 | 9.844E-02 | NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 6.179E-02 | 9.844E-02 | NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 6.066E-02 | 9.844E-02 | NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 6.066E-02 | 9.844E-02 | NFKB1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 6.349E-02 | 9.844E-02 | NFKB1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | CNR1; TRPV1; |
NA: NA | Esophagus sensitivity | NA | TRPV1; |
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CNR1; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR2; CNR1; TRPV1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2; |
C00-D49: Neoplasms | Ovarian cancer | C56 | CNR1; |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | CNR1; |
K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1; |
C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia | F50.0-F50.1 | CNR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | CNR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | CNR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | CNR1; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR2; CNR1; TRPV1; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CNR2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | CNR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CNR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CNR1; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CNR2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | CNR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; CNR1; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | CNR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | CNR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | CNR1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chemotherapy-induced nausea | R11 | CNR1; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | CNR1; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | CNR1; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | CNR2; TRPV1; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | TRPV1; |